X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3118) 3118
Publication (474) 474
Book Review (106) 106
Book Chapter (46) 46
Newsletter (34) 34
Book / eBook (26) 26
Newspaper Article (14) 14
Conference Proceeding (13) 13
Dissertation (5) 5
Data Set (1) 1
Magazine Article (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2217) 2217
index medicus (2061) 2061
animals (1134) 1134
hepatitis (975) 975
health aspects (664) 664
hepatitis c virus (564) 564
immunology (564) 564
virology (539) 539
gastroenterology & hepatology (529) 529
male (529) 529
viruses (510) 510
hepatitis c (509) 509
proteins (508) 508
female (506) 506
mice (497) 497
liver (472) 472
virus diseases (418) 418
hepatitis-c virus (403) 403
infections (399) 399
infection (393) 393
gene expression (368) 368
interferon (366) 366
signal transduction (359) 359
research (353) 353
research article (339) 339
medicine (332) 332
liver diseases (328) 328
expression (325) 325
pharmacology & pharmacy (323) 323
cell biology (314) 314
middle aged (311) 311
cytokines (309) 309
biochemistry & molecular biology (308) 308
inflammation (303) 303
analysis (300) 300
apoptosis (299) 299
microbiology (299) 299
article (298) 298
adult (294) 294
cell line (289) 289
cancer (274) 274
review (270) 270
liver cancer (268) 268
multidisciplinary sciences (268) 268
infectious diseases (267) 267
replication (265) 265
antiviral agents - pharmacology (256) 256
antiviral agents (255) 255
hepatocellular carcinoma (254) 254
digestive system diseases (239) 239
rodents (239) 239
biology (237) 237
hepatitis b (235) 235
science (234) 234
rna (232) 232
antiviral agents - therapeutic use (230) 230
oncology (220) 220
activation (215) 215
immune system (212) 212
hepacivirus - physiology (210) 210
cell line, tumor (206) 206
development and progression (206) 206
genetic aspects (200) 200
hepatitis b virus (200) 200
physiological aspects (200) 200
kinases (199) 199
biological response modifiers (198) 198
nf-kappa-b (197) 197
liver cirrhosis (195) 195
hepacivirus - drug effects (191) 191
viral infections (191) 191
gastroenterology and hepatology (187) 187
immune response (187) 187
care and treatment (186) 186
medicine, research & experimental (186) 186
chronic hepatitis-c (183) 183
hepatocellular-carcinoma (182) 182
risk factors (180) 180
t cells (179) 179
hepacivirus - genetics (177) 177
hiv (175) 175
aged (174) 174
pathogenesis (174) 174
medical research (172) 172
cells (168) 168
dendritic cells (168) 168
cells, cultured (166) 166
disease (166) 166
hepatology (166) 166
in-vitro (165) 165
fibrosis (161) 161
lymphocytes (161) 161
hcv (157) 157
hepatitis-b-virus (156) 156
hepatitis-c-virus (155) 155
mice, inbred c57bl (155) 155
virus replication - drug effects (155) 155
genomes (154) 154
hepatocytes (154) 154
innate immunity (151) 151
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Gastroenterology, ISSN 0016-5085, 10/2017, Volume 153, Issue 4, pp. 1107 - 1119.e10
Ligand binding to inhibitory receptors on immune cells, such as programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA4),... 
GPC3 | MAGEC2 | Immunotherapy | Galectin 9 | SAFETY | CANCER | RESPONSES | ADVANCED MELANOMA | PEPTIDE-MHC | NIVOLUMAB | GASTROENTEROLOGY & HEPATOLOGY | UP-REGULATION | PD-1 | TETRAMERS | EXHAUSTION | Tumor Escape - drug effects | Antigens, CD - immunology | Up-Regulation | Immunotherapy - methods | Coculture Techniques | Humans | Hepatitis A Virus Cellular Receptor 2 - metabolism | Tumor Microenvironment | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antigens, CD - metabolism | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Hepatitis A Virus Cellular Receptor 2 - antagonists & inhibitors | Carcinoma, Hepatocellular - drug therapy | T-Lymphocytes - metabolism | T-Lymphocytes - drug effects | Liver Neoplasms - pathology | Lymphocytes, Tumor-Infiltrating - metabolism | Antineoplastic Agents - pharmacology | Carcinoma, Hepatocellular - immunology | Hepatitis A Virus Cellular Receptor 2 - immunology | Cytokines - metabolism | Antibodies, Monoclonal - pharmacology | Cells, Cultured | Liver Neoplasms - drug therapy | CTLA-4 Antigen - metabolism | Programmed Cell Death 1 Receptor - metabolism | Antibodies, Neutralizing - pharmacology | Liver Neoplasms - immunology | Lymphocytes, Tumor-Infiltrating - drug effects | CTLA-4 Antigen - immunology | Signal Transduction - drug effects | Lymphocyte Activation - drug effects | Carcinoma, Hepatocellular - pathology | Liver Neoplasms - metabolism | T-Lymphocytes - immunology | Cell Proliferation - drug effects | Programmed Cell Death 1 Receptor - immunology | CTLA-4 Antigen - antagonists & inhibitors | Carcinoma, Hepatocellular - metabolism | Lymphocytes, Tumor-Infiltrating - immunology | Viral antibodies | Cell death | Analysis | Melanoma | Antibodies | T cells | Lung cancer, Non-small cell | Cancer | Liver cancer | Dendritic cells | Tumor antigens | Lung cancer | Immunity
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2017, Volume 74, pp. 55 - 72
Abstract Recent success in cancer immunotherapy (anti-CTLA-4, anti-PD1/PD-L1) has confirmed the hypothesis that the immune system can control many cancers... 
Hematology, Oncology and Palliative Medicine | Molecular biology | Clinical development | Immuno-oncology | Novel antibodies | OX40 | NATURAL-KILLER-CELLS | SOLID TUMORS | CD4(+) T-CELLS | CANCER-IMMUNOTHERAPY | LUNG-CANCER | THERAPY | NK CELLS | ONCOLOGY | PHASE-I TRIAL | MONOCLONAL-ANTIBODIES | T-Lymphocyte Subsets - immunology | Immunotherapy - methods | Humans | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | B7 Antigens - immunology | Inducible T-Cell Co-Stimulator Protein - agonists | Glucocorticoid-Induced TNFR-Related Protein - drug effects | OX40 Ligand - agonists | Hepatitis A Virus Cellular Receptor 2 - antagonists & inhibitors | Lymphocyte Activation - immunology | Neoplasms - therapy | Immunity, Cellular - physiology | Killer Cells, Natural - immunology | Tumor Necrosis Factor Receptor Superfamily, Member 9 - agonists | Cytokines - immunology | T-Lymphocytes, Cytotoxic - immunology | Antibodies, Monoclonal, Humanized - therapeutic use | CD40 Antigens - agonists | Antigens, CD - drug effects | B7 Antigens - antagonists & inhibitors | B-Lymphocytes - immunology | Neoplasms - immunology | Major Histocompatibility Complex - immunology | CTLA-4 Antigen - antagonists & inhibitors | Indoleamine-Pyrrole 2,3,-Dioxygenase - antagonists & inhibitors | Receptors, KIR - antagonists & inhibitors | Drugs | Chemotherapy | Cell death | Immunotherapy | Monoclonal antibodies | Control systems | T cells | Cancer
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 01/2017, Volume 23, Issue 1, pp. 124 - 136
Purpose: Checkpoint molecules like programmed death-1 (PD-1) and T-cell immunoglobulin mucin-3 (TIM-3) are negative immune regulators that may be upregulated... 
TGF-BETA | DENDRITIC CELLS | RECEPTOR TIM-3 | ONCOLOGY | IMMUNE-RESPONSES | APOPTOTIC CELLS | REGULATORY T-CELLS | CANCER-IMMUNOTHERAPY | ANTITUMOR IMMUNITY | RESEARCH PLATFORM | BLOCKADE | Humans | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Molecular Targeted Therapy | Glioma - metabolism | Hepatitis A Virus Cellular Receptor 2 - antagonists & inhibitors | Lymphocytes - immunology | Glioma - pathology | Glioma - therapy | Female | Lymphocytes, Tumor-Infiltrating - metabolism | Radiosurgery - methods | Disease Models, Animal | Lymphocytes - metabolism | Tumor Microenvironment - drug effects | Glioma - immunology | Programmed Cell Death 1 Receptor - metabolism | Immunophenotyping | Treatment Outcome | Combined Modality Therapy | Lymphocytes, Tumor-Infiltrating - drug effects | Antineoplastic Agents, Immunological - pharmacology | Tumor Microenvironment - immunology | Animals | Lymphocytes - drug effects | Survival Analysis | Biomarkers | Immunologic Memory | Mice | Lymphocytes, Tumor-Infiltrating - immunology | Therapy | Regulators | PD-1 protein | Brain tumors | Glioblastoma | Radiation | Lymphocytes T | Immunity | Metastases | Anticancer properties | Lymphocytes | Surgery | Glioma cells | Immunological memory | Immune response | Tumor-infiltrating lymphocytes | Survival | Glioblastoma multiforme | Mucin | Experimental design | Radiology | Antitumor activity | Infiltration | Cancer | Apoptosis
Journal Article
Human Reproduction, ISSN 0268-1161, 04/2016, Volume 31, Issue 4, pp. 700 - 711
Abstract STUDY QUESTION Are the immune regulatory molecules programmed cell death-1 (PD-1) and T-cell immunoglobulin mucin-3 (Tim-3) involved in regulating... 
CD4+T | miscarriage | Th2 bias | pregnancy | trophoblast | PD-1 | Tim-3 | ALLOGRAFT-REJECTION | IMMUNITY | PROTECTION | THYMIC STROMAL LYMPHOPOIETIN | OBSTETRICS & GYNECOLOGY | REPRODUCTIVE BIOLOGY | COSTIMULATORY PATHWAYS | CD4(+)T | DIFFERENTIATION | PDL1 | EXHAUSTION | FETOMATERNAL TOLERANCE | Abortion, Habitual - pathology | Fetal Resorption - prevention & control | Coculture Techniques | Humans | Hepatitis A Virus Cellular Receptor 2 - metabolism | Abortion, Habitual - immunology | Fetal Resorption - metabolism | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Th2 Cells - immunology | CD4-Positive T-Lymphocytes - pathology | Abortion, Habitual - metabolism | Pregnancy Trimester, First | Programmed Cell Death 1 Receptor - blood | Th2 Cells - drug effects | Abortion, Induced | CD4-Positive T-Lymphocytes - immunology | Hepatitis A Virus Cellular Receptor 2 - antagonists & inhibitors | Abortion, Habitual - blood | Antibodies, Neutralizing - therapeutic use | Female | Fetal Resorption - pathology | Maternal-Fetal Exchange - drug effects | Th2 Cells - pathology | Immune Tolerance - drug effects | Decidua - immunology | CD4-Positive T-Lymphocytes - metabolism | Cells, Cultured | Hepatitis A Virus Cellular Receptor 2 - blood | Programmed Cell Death 1 Receptor - metabolism | Antibodies, Neutralizing - pharmacology | Decidua - pathology | Fetal Resorption - immunology | Th2 Cells - metabolism | Decidua - metabolism | Pregnancy | Tocolytic Agents - pharmacology | Tocolytic Agents - therapeutic use | Animals | Cell Proliferation - drug effects | Mice | Decidua - drug effects | CD4-Positive T-Lymphocytes - drug effects | Crosses, Genetic
Journal Article
Journal of Hematology and Oncology, ISSN 1756-8722, 05/2017, Volume 10, Issue 1, pp. 103 - 16
Inhibitory molecules such as PD-1, CTLA-4, LAG-3, or TIM-3 play a role to keep a balance in immune function. However, many cancers exploit such molecules to... 
PD-L1 | PD-L2 | Hematologic malignancies | CTLA-4 | Immune checkpoint | PD-1 | MULTIPLE-MYELOMA | PD-1 BLOCKADE | BRENTUXIMAB VEDOTIN | ACUTE MYELOID-LEUKEMIA | CD8(+) T-CELLS | B-CELL LYMPHOMA | ONCOLOGY | CLASSICAL HODGKIN LYMPHOMA | DEATH LIGAND 1 | HEMATOLOGY | NF-KAPPA-B | Tumor Escape - drug effects | B7-H1 Antigen - physiology | Humans | Hepatitis A Virus Cellular Receptor 2 - physiology | Neoplasm Proteins - antagonists & inhibitors | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Clinical Trials as Topic | Antigens, CD - drug effects | Programmed Cell Death 1 Receptor - physiology | Molecular Targeted Therapy | Antigen-Presenting Cells - immunology | Biomarkers, Tumor | Patient Selection | Antineoplastic Agents, Immunological - adverse effects | Hepatitis A Virus Cellular Receptor 2 - antagonists & inhibitors | B7-H1 Antigen - antagonists & inhibitors | Multicenter Studies as Topic | Antineoplastic Agents, Immunological - therapeutic use | Lymphocyte Activation - drug effects | Hematologic Neoplasms - drug therapy | Antigens, CD - physiology | CTLA-4 Antigen - antagonists & inhibitors | CTLA-4 Antigen - physiology | PD-1 protein | Lung cancer | Clinical trials | Recovery of function | Cytotoxicity | Biology | CD223 antigen | Myeloma | Myelodysplastic syndrome | Proteins | CTLA-4 protein | Immunology | Lymphocytes | Immunotherapy | Janus kinase 2 | Antigens | Immunoglobulins | Immune response | Hematology | Myeloid leukemia | Melanoma | Immunosurveillance | T cell receptors | Lymphoma | PD-L1 protein | Biomarkers | Ligands | Lymphomas | Acute myeloid leukemia | Binding sites | Hodgkin's disease | Apoptosis
Journal Article
Clinical Immunology, ISSN 1521-6616, 10/2017, Volume 183, pp. 167 - 173
Persistent stimulation with antigens derived from viruses that establish chronic infections or tumour antigens results in the exhaustion of T cells.... 
HIV-1 | Coinhibitory receptors | CD160 | LAG-3 | BTLA | T cell exhaustion | CTLA-4 | Immune checkpoints | TIM-3 | PD-1 | PERSISTENCE | EFFECTOR FUNCTION | INHIBITORY RECEPTORS | INDUCTION | IMMUNOLOGY | CHRONIC VIRAL-INFECTION | MELANOMA | ANTITUMOR IMMUNITY | EXPRESSION | EXHAUSTION | IPILIMUMAB | Antigens, CD - immunology | GPI-Linked Proteins - immunology | HIV Infections - virology | Humans | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antibodies, Blocking - pharmacology | Ipilimumab - pharmacology | Receptors, Immunologic - antagonists & inhibitors | HIV Infections - immunology | HIV-1 - immunology | Hepatitis A Virus Cellular Receptor 2 - antagonists & inhibitors | Flow Cytometry | Cytokines - drug effects | HIV Antigens - immunology | T-Lymphocytes - drug effects | Antibodies, Monoclonal, Humanized - pharmacology | CD8-Positive T-Lymphocytes - drug effects | Antineoplastic Agents - pharmacology | Programmed Cell Death 1 Receptor - immunology | Receptors, Immunologic - immunology | GPI-Linked Proteins - antagonists & inhibitors | Hepatitis A Virus Cellular Receptor 2 - immunology | Immunologic Factors - pharmacology | Cytokines - immunology | Viral antibodies | Highly active antiretroviral therapy | Antigens | Medical colleges | Analysis | Antibodies | Fatigue | Hepatitis C | T cells | HIV (Viruses) | Health aspects
Journal Article
Molecular Therapy, ISSN 1525-0016, 04/2017, Volume 25, Issue 4, pp. 962 - 975
Systemic viroimmunotherapy activates endogenous innate and adaptive immune responses against both viral and tumor antigens. We have shown that therapy with... 
oncolytic virotherapy | checkpoint inhibitors | tumor therapy | MEDICINE, RESEARCH & EXPERIMENTAL | CD8(+) T-CELLS | MELANOMA | IMMUNOVIROTHERAPY | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | GENETICS & HEREDITY | INFECTION | ANTITUMOR IMMUNITY | DYSFUNCTION | VESICULAR STOMATITIS-VIRUS | TIM-3 | PD-1 | EXHAUSTION | T-Lymphocyte Subsets - immunology | Antigens, Neoplasm - genetics | Vesicular stomatitis Indiana virus - genetics | Antigens, Neoplasm - immunology | Melanoma, Experimental - therapy | Mortality | Hepatitis A Virus Cellular Receptor 2 - metabolism | Melanoma, Experimental - pathology | Programmed Cell Death 1 Receptor - metabolism | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Treatment Outcome | Adoptive Transfer | Genetic Vectors - genetics | Hepatitis A Virus Cellular Receptor 2 - antagonists & inhibitors | Neoplasm Metastasis | Animals | Melanoma, Experimental - genetics | Melanoma, Experimental - immunology | T-Lymphocyte Subsets - metabolism | Immunotherapy | Female | Immunologic Memory | Mice | Disease Models, Animal | Flow cytometry | Peptides | PD-1 protein | CD8 antigen | Effector cells | Viruses | Lymphocytes T | Metastasis | Success | Metastases | Lymphocytes | Oncolysis | Immune system | Medical research | Antigens | Cell survival | Statistical analysis | Survival analysis | Stomatitis | Immune checkpoint | Antigen (tumor-associated) | Monoclonal antibodies | Software | Cancer | Tumors | Original
Journal Article
Journal Article
Clinical Immunology, ISSN 1521-6616, 07/2018, Volume 192, pp. 78 - 84
Journal Article